

Reference:	FOI.21479.26
Subject:	Biologics in Dermatology
Date of Request:	1 September 2026

Requested:

1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
 - Adalimumab - Humira
 - Adalimumab Biosimilar
 - Apremilast - Otezla
 - Apremilast generic
 - Bimekizumab
 - Brodalumab
 - Certolizumab
 - Deucravacitinib
 - Dimethyl fumarate
 - Etanercept - Enbrel
 - Etanercept Biosimilar
 - Guselkumab
 - Infliximab - Remicade
 - Infliximab Biosimilar
 - Ixekizumab
 - Risankizumab
 - Secukinumab
 - Tildrakizumab
 - Ustekinumab - Stelara
 - Ustekinumab Biosimilar
 - Omalizumab
 - Spesolimab

2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:
 - Adalimumab - Humira
 - Adalimumab Biosimilar
 - Bimekizumab
 - Certolizumab
 - Infliximab - Remicade
 - Infliximab Biosimilar
 - Secukinumab
 - Ustekinumab - Stelara
 - Ustekinumab Biosimilar

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients due to the low number (less than 5) and have therefore, replaced the figures in the tables with an asterisk (*), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act. This

information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB provides within the table below, the number of Dermatology patients treated for any medical condition, with the listed medications, during the period 1 June to 31 August 2026.

Medication	Number
Adalimumab - Humira	*
Adalimumab Biosimilar	105
Apremilast - Otezla	0
Apremilast generic	10
Bimekizumab	5
Brodalumab	*
Certolizumab	0
Deucravacitinib	0
Dimethyl fumarate	0
Etanercept - Enbrel	0
Etanercept Biosimilar	*
Guselkumab	*
Infliximab - Remicade	0
Infliximab Biosimilar	0
Ixekizumab	0
Risankizumab	39
Secukinumab	37
Tildrakizumab	*
Ustekinumab - Stelara	0
Ustekinumab Biosimilar	29
Omalizumab	19
Spesolimab	0

2. The UHB provides within the table below the number of Dermatology patients treated for Hidradenitis Suppurativa (HS), with the listed medications, during the period 1 June to 31 August 2026.

Medication	Number
Adalimumab - Humira	0
Adalimumab Biosimilar	16
Bimekizumab	0
Certolizumab	0
Infliximab - Remicade	0
Infliximab Biosimilar	0
Secukinumab	*
Ustekinumab - Stelara	0
Ustekinumab Biosimilar	0

